Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 8/20 | 0.41 |
| ▸ | RAF1 | P04049 | 6/20 | 0.41 |
| ▸ | KRAS | P01116 | 5/20 | 0.41 |
| ▸ | KDR | P35968 | 5/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.40 |
| ▸ | SIK2 | Q9H0K1 | 5/20 | 0.37 |
| ▸ | SIK3 | Q9Y2K2 | 3/20 | 0.37 |
| ▸ | SIK1 | P57059 | 2/20 | 0.37 |
| ▸ | GAK | O14976 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.37 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.37 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.37 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.37 |
| ▸ | EPHB1 | P54762 | 1/20 | 0.37 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5056344 | 0.91 | BRAF (0.40) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL5056401 | 0.90 | BRAF (0.40) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL5062082 | 0.90 | BRAF (0.43) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL5056310 | 0.86 | BRAF (0.40) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL5056308 | 0.84 | BRAF (0.42) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL5054853 | 0.83 | BRAF (0.44) | BRAFRAF1SIK2ABL1MEN1 | |
| SCHEMBL4276391 | 0.83 | BRAF (0.46) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL4430448 | 0.81 | BRAF (0.44) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL5067015 | 0.81 | BRAF (0.46) | BRAFRAF1KRASKDRMAP2K2 | |
| SCHEMBL5056276 | 0.81 | BRAF (0.42) | BRAFRAF1KRASKDRMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | BRAF 2/4885RAF1 55/4885KRAS 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.